Prescient Therapeutics takes cap raise to $9.8m to fast-track cancer treatment
Special Report: Prescient Therapeutics has raised $3m in a placement to sophisticated and professional investors following...
Special Report: Prescient Therapeutics has raised $3m in a placement to sophisticated and professional investors following...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) on Wednesday issued results for the June quarter highlighting the first...
Prescient Therapeutics has entered a critical stage where clinical data, regulatory support, and commercial potential...
In a sector where the right drug emerging at the right time can yield billions, Prescient...
Prescient Therapeutics (ASX: PTX) is fast emerging as the newest developer of an advanced cancer drug...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
While part of the story is an increased ability to diagnose cancers early, thanks to...
Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the company’s latest milestone —...
Prescient Therapeutics has reached a key milestone in its clinical development program, initiating its first...

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.